Business Wire

BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders

Del

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors intends to set a new record date for the distribution of AgeX Therapeutics, Inc. (“AgeX”) shares to BioTime shareholders. The ratio of one share of AgeX common stock for every 10 shares of BioTime common stock will remain unchanged. A new date provides time to complete necessary administrative activities and receive all regulatory approvals.

“BioTime remains committed to distributing AgeX shares to BioTime shareholders promptly following clearance from the Securities and Exchange Commission, the New York Stock Exchange (NYSE), and completion of related administrative events. We remain strongly positioned to complete the key initiatives of simplification of BioTime’s corporate and operating structure and the unlocking of shareholder value from non-core assets,” said Adi Mohanty, co-CEO.

Details on the AgeX Distribution

A new record date for the distribution of AgeX shares owned by BioTime on a pro rata basis to eligible BioTime shareholders will be announced once it is set by the Board of Directors.

BioTime shareholders will not be required to take any action in order to receive shares of AgeX common stock through this distribution, meaning that they will not have to surrender or exchange BioTime common stock in order to receive shares of AgeX common stock.

For more detail on AgeX’s business, risk factors, and uncertainties, shareholders should carefully review the AgeX Information Statement filed as an exhibit to its Registration Statement on Form 10 filed with the SEC at www.sec.gov. Copies of a definitive Information Statement relating to the distribution will be mailed to all BioTime shareholders entitled to receive AgeX common stock in the distribution.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company focused on degenerative diseases. Its clinical programs are based on two platform technologies: cell replacement and cell/drug delivery. With its cell replacement platform, BioTime is producing new cells and tissues with its proprietary pluripotent cell technologies. These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases or injuries. BioTime’s cell/drug delivery programs are based upon its proprietary HyStem® cell and drug delivery hydrogel matrix technology. HyStem® was designed, in part, to provide for the transfer, retention and/or engraftment of cellular replacement therapies. HyStem® is a unique hydrogel that has been shown to support cellular attachment and proliferation in vivo. Current research at leading medical institutions has shown that HyStem® is compatible with a wide variety of cells and tissue types including brain, bone, skin, cartilage, vascular and heart tissues. Due to the unique cross-linking chemistry, HyStem® hydrogels have the ability to mix cells, biologics and small molecule drugs and can be injected or applied as a gel which allows the hydrogel to conform to a cavity or space. This property of HyStem® hydrogels offers several distinct advantages over other hydrogels, including the possibility of combining bioactive materials with the hydrogel at the point of use. BioTime is also developing HyStem® for the delivery of therapeutic drugs and cells to localized areas of the body, including for sustained drug release in the targeted anatomical sites. BioTime’s lead cell delivery clinical program is Renevia®, which consists of HyStem® combined with the patient's own adipose (fat) derived tissue or cells. Renevia® met its primary endpoint in an EU pivotal clinical trial for the treatment of facial lipoatrophy in HIV patients in 2017. BioTime has submitted Renevia® for CE Mark approval in the EU. There were no device related serious adverse events reported to date. BioTime’s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy, which is in a Phase I/IIa multicenter clinical trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. There have been no unexpected serious adverse events reported to date. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.

BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on TwitterLinkedInFacebookYouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotime.com.

About AgeX Therapeutics

AgeX Therapeutics, Inc., an affiliate of BioTime, Inc. (NYSE American: BTX), is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease. The company’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using the Company’s UniverCyte technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology. Renelon™ is a first-generation iTR product designed to promote scarless tissue repair which the Company plans to initially develop as a topically-administered device for commercial development through a 510(k) application. In addition to the product candidates in early development, the company, through its LifeMap subsidiary, currently markets genomic interpretation algorithms. In addition, the company, through its ESI BIO division, markets Cytiva®, comprised of PSC-derived heart muscle cells used in screening drugs for efficacy and safety.

For more information, please visit www.agexinc.com or connect with the company on TwitterFacebook and YouTube.

Forward-Looking Statements

Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Investors are cautioned that statements in this press release regarding: (a) any value to BioTime shareholders of the remaining AgeX common stock or the promissory note from Juvenescence and the potential for liquidity of those assets; (b) BioTime's plans or expectations for distribution of AgeX common stock to BioTime shareholders; (c) potential listing and value appreciation of AgeX common stock on the NYSE American; (d) whether the relationship with AgeX and Juvenescence can lead to increase value for shareholders; (e) BioTime’s cash sufficiency forecast, including its projected cash burn and proceeds from the Juvenescence transaction; (f) potential milestone and royalty payments; (g) whether the Juvenescence transaction will generate the expected liquidity and flexibility for BioTime to support its operations and plans through the clinical and other results projected and whether those events will occur as currently anticipated. Forward-looking statements involve risks and uncertainties. These risks and uncertainties, include, without limitation: (i) the possibility that BioTime shareholders may realize little or no value from the AgeX common stock or from the Juvenescence transaction; (ii) the potential inability of BioTime to complete the distribution in a timely manner or at all, including as a result of the failure of BioTime and/or AgeX to obtain or maintain required federal and state registrations and qualifications necessary to enable the distribution, and related transactions; (iii) the possibility of litigation that could arise as a result of or in connection with the Juvenescence transaction, distribution or related transactions; (iv) that there is no existing public market for AgeX or Juvenescence common stock, nor may a public market for such securities ever develop; and (v) that BioTime may require additional financing to fund its programs. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of BioTime’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. BioTime specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Contact information

BioTime Investor and Media Contact:
David Nakasone, 510-871-4188
Dnakasone@biotime.com
Or
Media Contact for AgeX:
Gotham Communications, LLC
Bill Douglass, 646-504-0890
bill@gothamcomm.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Panasonic Signs Joint Business Development Agreement with Startup Linkwiz to Enhance Welding Processes in Manufacturing17.6.2019 10:03:00 CESTPressemelding

On June 17, 2019, Panasonic Corporation (TOKYO: 6752) announced that it has signed a joint business development agreement with Linkwiz, Inc. — a startup company specializing in the development and sales of autonomous robotic system software and technical consulting — to develop solutions to enhance welding processes in the manufacturing field. The agreement is being undertaken by Panasonic’s Connected Solutions Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005360/en/ Yasu Higuchi, CEO of Panasonic's Connected Solutions Company (left) and Go Fukino, President of Linkwiz, Inc. (right) (Photo: Business Wire) Under its “Gemba Process Innovation” vision, Panasonic is expanding its B2B solutions business. “The ‘gemba,’ or physical site for frontline operations, is where value is generated and problems must be confronted,” explained Yasu Higuchi, CEO of the Connected Solutions Company. “By applying our 100-years of

Norsk Titanium & QuesTek Test Additive Titanium Alloy17.6.2019 10:00:00 CESTPressemelding

Building upon the collaboration announced at Farnborough in July 2018, Norsk Titanium (Norsk) has successfully printed QuesTek’s custom titanium wire in support of initial material properties testing. QuesTek thoroughly evaluated the microstructure and measured the properties in several heat-treated conditions including various combinations of stress relief and solution treatment. Superior performance versus Ti-6-4 has been demonstrated. The highest performance condition was a basic one-hour solution treatment where an average Ultimate Tensile Strength (UTS) of 147 ksi and an average elongation of 18% was measured. This represents an increase in both strength and elongation, while maintaining fatigue performance, over standard Ti-6Al-4V. “QuesTek’s high-performance titanium alloy provides an opportunity for Norsk’s customers to optimize components printed with Norsk Titanium’s RPD™ process and opens doors for new applications,” said Norsk Chief Technology Officer Carl Johnson. The typi

H.I.G. Europe to Acquire Polyurethane Systems Business from Covestro17.6.2019 08:05:00 CESTPressemelding

H.I.G. Capital, LLC ("H.I.G."), a leading global private equity investment firm with over €26 billion of equity capital under management, is pleased to announce that an affiliate has signed a definitive agreement to acquire the European Polyurethane Systems Business (the “Company”) in a carve-out transaction from Covestro AG. The transaction is subject to clearing by the relevant antitrust authorities with closing anticipated for the second half of 2019. The European Polyurethane Systems Business operates four systems houses in Germany, Denmark, the Netherlands and Spain. It employs approximately 250 full-time employees and generates annual sales of approximately €230 million. Systems houses develop and formulate tailor-made ready-to-use chemical blends for the production of a wide range of polyurethane products such as insulation materials, foams, shoe soles, and building materials. The Company serves a wide range of small- and mid-sized customers across Europe and will be led by Dr.

Appointment of Mark Wood as Chairman of HomeServe Labs17.6.2019 08:00:00 CESTPressemelding

HomeServe plc (“HomeServe”, “the Group”), the international home repairs and improvements business, is pleased to announce the appointment of Mark Wood CBE as non-Executive Chairman of HomeServe Labs, the unit within HomeServe that developed LeakBot. HomeServe Labs is the innovation arm of HomeServe which in 2016 launched LeakBot, a patented smart leak alarm that can detect leaks anywhere on a mains water system. Water leaks are one of the major causes of claims on home insurance policies across Western Europe and the US, and LeakBot is designed specifically to help insurance companies prevent water leak claims by catching the leaks early. Craig Foster, LeakBot CEO, said: "Mark Wood is a previous CEO of AXA and a veteran of the insurance industry. This experience will really benefit us as a B2B Insuretech. Mark is also a successful entrepreneur himself, and more recently added a huge amount of value to promising fintech start-ups like PensionBee. With Mark on board as our new Chairman,

TYAN Powers AI and HPC with 2nd Gen Intel® Xeon® Scalable Processor-based Server Platforms at ISC 201917.6.2019 08:00:00 CESTPressemelding

TYAN®, an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, is showcasing its new 2nd gen Intel® Xeon® Scalable processor-based platforms that are optimized for predictive analytics, machine learning, and HPC applications at ISC 2019 from June 17-19 at Messe Frankfurt, booth C-1250. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005020/en/ TYAN's Thunder HX Lineup Designed for AI Optimization and HPC Revolution (Photo: Business Wire) “The most demanding workloads including HPC, AI deep learning, data analytics, and multi-cloud infrastructure require maximum performance across compute, memory, storage, and network resources, “said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “2nd gen Intel Xeon Scalable processors provide a powerful foundation for TYAN server platforms that enables us to deliver performance enhanceme

Norsk Titanium Announces Larger Capacity Rapid Plasma Deposition™ (RPD™) Machine17.6.2019 08:00:00 CESTPressemelding

Officials with Norsk Titanium (Norsk) announced today the company has designed and is currently building a larger-scale Rapid Plasma Deposition™ (RPD™) machine. This new machine enables manufacturing of larger, more complex aircraft and engine components, at faster print speeds. The new RPD™ machine, the G-IVL, will use the same advanced RPD™ technology of Norsk’s current additive manufacturing process. Norsk’s patented RPD™ technology and equipment utilizes proprietary process controls to melt titanium wire with plasma torches, in an argon environment to produce near-net shape components for airframe and aircraft engine applications. The Norsk G-IVL machine will expand the printing envelope to 190cm by 40cm by 60cm. It will print double-sided, as well as single-sided components, of complex geometries and deposit material in excess of 8kg per hour. The resultant component will have the material qualities equivalent to forgings. “The G-IVL machine will significantly expand Norsk’s capab